PHI with Regional ileitis
How does this condition affect your private health insurance?
Ileitis regionalis, also known as Crohn's disease, is a chronic inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to anus, though it most commonly targets the small intestine, particularly the ileum. It is characterized by transmural inflammation, meaning it affects all layers of the bowel wall, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The inflammation can be patchy, with healthy sections of bowel interspersed between diseased areas. Its exact cause is unknown but is believed to involve a combination of genetic predisposition, immune system dysfunction, and environmental factors. There is currently no cure, and treatment focuses on managing symptoms and inducing remission, often involving medications and sometimes surgery to remove affected segments.
PKV Risk Assessment
However, some specialized PHI providers may insure you with a surcharge of up to 60%.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months for initial symptomatic presentation leading to diagnosis.
Duration of Illness (Lifetime)
Chronic disease, lifelong with periods of remission and flare-ups.
Cost of Treatment (Initial)
High, including diagnostic procedures (endoscopy, imaging) and initial medication regimens, potentially thousands of dollars.
Cost of Treatment (Lifetime)
Very high, potentially hundreds of thousands to millions of dollars due to chronic medication, regular monitoring, potential hospitalizations, and surgical interventions.
Mortality Rate
Low, but complications like perforation, severe infection, or long-term colorectal cancer risk can increase mortality.
Risk of Secondary Damages
High. Includes bowel obstruction, fistulas, abscesses, malnutrition, anemia, arthritis, skin lesions, eye inflammation, kidney stones, osteoporosis, and increased risk of colorectal cancer.
Probability of Full Recovery
Very low, as it is a chronic disease with no definitive cure. Management aims for remission, but the disease often recurs.
Underlying Disease Risk
Moderate. Patients may have other autoimmune conditions (e.g., primary sclerosing cholangitis), or conditions like irritable bowel syndrome (IBS) may initially mimic symptoms.